Research ArticleOncology
Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
Rudolf A. Werner, Jan-Stefan Schmid, Takahiro Higuchi, Mehrbod S. Javadi, Steven P. Rowe, Bruno Märkl, Christoph Aulmann, Martin Fassnacht, Matthias Kroiss, Christoph Reiners, Andreas K. Buck, Michael C. Kreissl and Constantin Lapa
Journal of Nuclear Medicine May 2018, 59 (5) 756-761; DOI: https://doi.org/10.2967/jnumed.117.199778
Rudolf A. Werner
1Department of Nuclear Medicine, University Hospital, University of Würzburg, Würzburg, Germany
2Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Jan-Stefan Schmid
1Department of Nuclear Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Takahiro Higuchi
1Department of Nuclear Medicine, University Hospital, University of Würzburg, Würzburg, Germany
3Department of Bio-Medical Imaging, National Cardiovascular and Cerebral Research Center, Osaka, Japan
Mehrbod S. Javadi
2Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Steven P. Rowe
2Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
Bruno Märkl
4Institute for Pathology, Hospital Augsburg, Augsburg, Germany
Christoph Aulmann
5Medical Department II, Hospital Augsburg, Augsburg, Germany
Martin Fassnacht
6Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany
7Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany
Matthias Kroiss
6Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany
7Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany
Christoph Reiners
1Department of Nuclear Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Andreas K. Buck
1Department of Nuclear Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Michael C. Kreissl
8Department of Nuclear Medicine, Hospital Augsburg, Augsburg, Germany; and
9Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany
Constantin Lapa
1Department of Nuclear Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 5
May 1, 2018
Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
Rudolf A. Werner, Jan-Stefan Schmid, Takahiro Higuchi, Mehrbod S. Javadi, Steven P. Rowe, Bruno Märkl, Christoph Aulmann, Martin Fassnacht, Matthias Kroiss, Christoph Reiners, Andreas K. Buck, Michael C. Kreissl, Constantin Lapa
Journal of Nuclear Medicine May 2018, 59 (5) 756-761; DOI: 10.2967/jnumed.117.199778
Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
Rudolf A. Werner, Jan-Stefan Schmid, Takahiro Higuchi, Mehrbod S. Javadi, Steven P. Rowe, Bruno Märkl, Christoph Aulmann, Martin Fassnacht, Matthias Kroiss, Christoph Reiners, Andreas K. Buck, Michael C. Kreissl, Constantin Lapa
Journal of Nuclear Medicine May 2018, 59 (5) 756-761; DOI: 10.2967/jnumed.117.199778